BUZZ - RPM shares drop as downgraded outlook overshadows Q1 earnings beat
路透社2026/10/06 12:56October 6 – ** Paint manufacturer RPM International (RPM.N) shares fell 2% to close at $93.50 after releasing its first-quarter earnings report ** The company expects mid-single-digit growth in adjusted EBITDA for fiscal year 2027, compared to its previous forecast of 5% to 10% ** The company expects consolidated sales to achieve mid-single-digit growth, roughly in line with the previous estimate of 3% to 7% ** According to LSEG data, net sales for the first quarter were $2.22 billions, meeting analysts’ expectations ** Adjusted earnings per share for the first quarter were $1.98, higher than the expected $1.94 ** Out of 18 brokerages, 17 gave a “buy” or higher rating, 1 gave a “hold” rating; the median price target is $127.94—data compiled by LSEG ** As of the previous trading day’s close, the stock has fallen 8.37% year-to-date (To facilitate non-English speakers, Reuters has automated its reports into several other languages. As automated translations may contain errors or may lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them as a convenience to readers. Reuters assumes no liability for any harm or loss arising from the use of automatic translation functions.)
October 6 - ** After the paint manufacturer RPM International (RPM.N) released its first quarter financial report, its share price fell by 2%, closing at $93.50
** The company expects its adjusted EBITDA for fiscal year 2027 to grow in the mid-single digits, previously anticipated at 5% to 10%
** The company expects consolidated sales to grow in the mid-single digits, generally in line with the previous forecast of 3% to 7%
** According to LSEG data, first quarter net sales were $2.22 billion, in line with analysts’ expectations
** First quarter adjusted earnings per share were $1.98, higher than the expected $1.94
** Of the 18 brokerages, 17 rated the stock “buy” or higher, and 1 rated it “hold”; the median target price is $127.94—data compiled by LSEG
** As of the close of the previous trading day, the stock had fallen 8.37% year-to-date
(To assist non-English speakers, Reuters provides automated translations of its reports in several other languages. Due to potential errors in automated translation or missing context, Reuters does not guarantee the accuracy of the automated translation text and offers it for readers’ convenience only. Reuters accepts no liability for any damage or loss caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
